EZH2 and cervical cancer: In the present study, we demonstrated that EZH2 was up-regulated during the development and progression of cervical cancer and that the down-regulation of EZH2 using CRISPR-Cas9 knockout technology and shRNA in cervical cancer cells inhibited cell growth both in vitro and in vivo by inhibiting Wnt/β-catenin signaling, which has key roles in embryonic development [25] and many cellular processes, such as proliferation, migration, differentiation and apoptosis [25–27].